Subject: Pembrolizumab Approved for Esophageal Cancer - Cancer Currents Blog
From: National Cancer Institute <[email-masked]>
To: [email-masked]
Date: Thu, 29 Aug 2019 14:32:29 +0000

Having trouble viewing this email? View it as a Web page.

You are subscribed to Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Recent posts are listed below.

Pembrolizumab Approved for Some Patients with Advanced Esophageal Cancer

08/28/2019

FDA has approved the immunotherapy drug pembrolizumab (Keytruda) to treat some patients with advanced esophageal cancer. Patients must have certain levels of the protein PD-L1 on their tumors, as determined by an FDA-approved test.

Stay Connected with the National Cancer Institute

Chat with us: LiveHelp       Call us: 1-800-4-CANCER (1-800-422-6237)

SUBSCRIBER SERVICES:
Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to [email-masked] using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892